单胺类神经递质
再摄取抑制剂
再摄取
去甲肾上腺素转运体
血清素转运体
抗抑郁药
重性抑郁障碍
血清素
无血性
心情
多巴胺
神经科学
心理学
机器学习
药理学
精神科
计算机科学
去甲肾上腺素
生物
医学
内科学
焦虑
受体
作者
Gustavo Henrique Marques Sousa,Renan Augusto Gomes,Eliseu Ortega de Oliveira,Gustavo Henrique Goulart Trossini
标识
DOI:10.1080/07391102.2022.2154269
摘要
Major depressive disorder (MDD) is characterized by a series of disabling symptoms like anhedonia, depressed mood, lack of motivation for daily tasks and self-extermination thoughts. The monoamine deficiency hypothesis states that depression is mainly caused by a deficiency of monoamine at the synaptic cleft. Thus, major efforts have been made to develop drugs that inhibit serotonin (SERT), norepinephrine (NET) and dopamine (DAT) transporters and increase the availability of these monoamines. Current gold standard treatment of MDD uses drugs that target one or more monoamine transporters. Triple reuptake inhibitors (TRIs) can target SERT, NET, and DAT simultaneously, and are believed to have the potential to be early onset antidepressants. Quantitative structure-activity relationship models were developed using machine learning algorithms in order to predict biological activities of a series of triple reuptake inhibitor compounds that showed in vitro inhibitory activity against multiple targets. The results, using mostly interpretable descriptors, showed that the internal and external predictive ability of the models are adequate, particularly of the DAT and NET by Random Forest and Support Vector Machine models. The current work shows that models developed from relatively simple, chemically interpretable descriptors can predict the activity of TRIs with similar structure in the applicability domain using ML methods.Communicated by Ramaswamy H. Sarma.
科研通智能强力驱动
Strongly Powered by AbleSci AI